https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42657 Wed 31 Aug 2022 13:02:26 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48710 Wed 29 Mar 2023 15:46:41 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54300 Wed 28 Feb 2024 15:46:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50274 70% of subjects receiving velusetrag 30 mg had GE normalization at 4 h. Treatment-emergent AEs were generally mild. Conclusions and Inferences: Velusetrag treatment was generally well-tolerated and associated with improved GE vs placebo in subjects with diabetic or idiopathic gastroparesis; however, only the lowest dose, velusetrag 5 mg, was associated with short-term improvement in gastroparesis symptoms.]]> Wed 28 Feb 2024 14:59:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50452 Wed 26 Jul 2023 13:14:54 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49619 2 GI tract areas are involved, the name should reflect all of the involved areas. Conclusions: This international process resulted in consensus for updated EGID nomenclature for both clinical and research use. EGID will be the umbrella term, rather than “eosinophilic gastroenteritis,” and specific naming conventions by location of GI tract involvement are recommended. As more data are developed, this framework can be updated to reflect best practices and the underlying science.]]> Wed 24 May 2023 11:40:45 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51280 Wed 20 Sep 2023 11:45:13 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55730 Wed 19 Jun 2024 09:48:29 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38722 Wed 19 Jan 2022 09:36:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37124 Wed 19 Aug 2020 10:39:42 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50280 Wed 15 May 2024 10:35:38 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54589 Wed 15 May 2024 08:46:39 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47086 0.05). Similar results were found for IBS subtypes. Higher serum L-arginine concentration had the strongest association with IBS diagnosis, with an odds ratio of 9.03 for those with serum L-arginine at the 75th (84 μmol/L) versus 25th (46 μmol/L) percentile (95% CI: 5.99–13.62). L-arginine had the best discriminative ability with a bias-adjusted area under the receiver operator characteristic curve of 0.859. Conclusions: Higher serum concentrations of L-arginine and endogenous methylarginines are strongly associated with IBS in adults.]]> Wed 14 Dec 2022 09:23:38 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50849 Wed 13 Mar 2024 15:39:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41179 Wed 12 Jul 2023 11:51:33 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52473 Wed 11 Oct 2023 20:43:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50841 Wed 09 Aug 2023 09:10:43 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50857 Wed 07 Feb 2024 15:20:00 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36862 Wed 07 Apr 2021 20:17:27 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44040 Wed 05 Oct 2022 15:32:28 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55535 Wed 05 Jun 2024 09:38:22 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49029 Wed 03 May 2023 12:44:55 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49006 Wed 03 May 2023 12:17:18 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41422 Wed 03 Aug 2022 12:06:41 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41421 Wed 03 Aug 2022 11:59:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55022 Wed 03 Apr 2024 15:28:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50715 Wed 02 Aug 2023 16:17:49 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49759 Tue 30 May 2023 18:25:04 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49755 Tue 30 May 2023 17:42:46 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55418 10 cigarettes/day during pregnancy was associated with a nearly 6-fold increased risk of CD in the offspring (OR 5.78, 95% CI 1.70–17.3). Breastfeeding (OR = 0.18, 95% CI 0.08–0.44) and iron supplementation during the first year of life (OR = 0.43, 95% CI 0.21–0.89) were negatively associated with CD. Conclusions: Smoking during pregnancy was associated with the risk of CD while Breastfeeding and oral iron supplementation at infancy were negatively associated with the risk of CD later in life.]]> Tue 28 May 2024 10:02:51 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54481 Tue 27 Feb 2024 15:05:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38873 Bacteroides species and describe the antimicrobial resistance biogeography along the intestine. We also detail which species, at which locations, are involved with the tryptophan/indole pathway, whose malfunctioning has been linked to pathologies including inflammatory bowel disease. Our study thus provides invaluable resources for investigating mechanisms connecting gut microbiota and host pathophysiology.]]> Tue 22 Feb 2022 16:36:25 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43462 P<.001). Higher non-GI somatic symptom scores were significantly associated with both symptom transitions (odds ratio, 3.9; 95% CI, 1.38 to 10.77) and having sustained symptoms (odds ratio, 12.7; 95% CI, 4.62 to 34.90). Conclusion: The overall population prevalence of chronic unexplained GI symptoms is stable, but in individuals, transitions seem to be the rule. As these various GI syndromes appear to be so intimately interconnected, the common underlying pathogenesis may account for a major subgroup of chronic unexplained GI disorders.]]> Tue 20 Sep 2022 08:49:21 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41593 Tue 19 Sep 2023 13:55:52 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55623 Tue 11 Jun 2024 16:02:37 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50115 Tue 11 Jul 2023 15:54:27 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52364 Tue 10 Oct 2023 14:16:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46015  0.5). Conclusions: In FD patients, the response to antimicrobial therapy with rifaximin is not influenced by concomitant IBS symptoms.]]> Tue 08 Nov 2022 18:38:07 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54158 Tue 06 Feb 2024 12:17:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54155 Tue 06 Feb 2024 12:11:04 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50052 Thu 29 Jun 2023 15:41:37 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50046 Thu 29 Jun 2023 14:52:42 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41178 Thu 28 Jul 2022 10:44:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45352 Thu 27 Oct 2022 11:46:53 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45328 30% response to the run-in diet, as measured by the Nepean Dyspepsia Index, were then re-challenged with 'muesli' bars containing either gluten, fructan, or placebo in randomised order. Those with symptoms which significantly reduced during the elimination diet, but reliably reappeared (a mean change in overall dyspeptic symptoms of >30%) with gluten or fructan re-challenge were deemed to have wheat induced FD. Results: Eleven participants were enrolled in the study (75% female, mean age 43 years). Of the initial cohort, nine participants completed the elimination diet phase of whom four qualified for the rechallenge phase. The gluten-free, low FODMAP diet led to an overall (albeit non-significant) improvement in symptoms of functional dyspepsia in the diet elimination phase (mean NDI symptom score 71.2 vs. 47.1, p = 0.087). A specific food trigger could not be reliably demonstrated. Conclusions: Although a gluten-free, low-FODMAP diet led to a modest overall reduction in symptoms in this cohort of FD patients, a specific trigger could not be identified. The modified Salerno criteria for NCG/WS identification trialled in this dietary rechallenge protocol was fit-for-purpose. However, larger trials are required to determine whether particular components of wheat induce symptoms in functional dyspepsia.]]> Thu 27 Oct 2022 08:44:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53983 Thu 25 Jan 2024 13:04:18 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51213 Thu 24 Aug 2023 14:59:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45598 Thu 23 Mar 2023 13:55:28 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41177 Thu 18 Apr 2024 12:11:34 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48867 Thu 13 Apr 2023 10:07:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48841 Thu 13 Apr 2023 09:46:22 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40611 Thu 11 Aug 2022 13:48:34 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46068 Thu 10 Nov 2022 14:23:04 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48154 Thu 09 Mar 2023 09:37:46 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49083 Thu 04 May 2023 09:25:22 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50509  3 bowel motions a day (OR 1.50, 95% CI 1.08, 2.07, p = 0.02; OR = 1.67, 95% CI 1.11, 2.51, p = 0.01), and loose stools (OR 1.40, 95% CI 1.04, 1.90, p = 0.03; OR = 1.68, 95% CI 1.13, 2.51, p = 0.01) at the 1- and 3-year follow-ups, respectively. Conclusions & Inferences: Diabetes is an independent risk factor for a greater frequency of early satiation and diarrhea, adjusting for lifestyle and psychological factors.]]> Thu 03 Aug 2023 11:12:36 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49117 Thu 02 May 2024 12:18:23 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46842 Thu 01 Dec 2022 16:04:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48476 Sun 19 Mar 2023 15:13:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49209 Sun 07 May 2023 09:29:54 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54035 Mon 29 Jan 2024 13:39:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51261 Mon 28 Aug 2023 14:59:19 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53921 Mon 22 Jan 2024 16:42:54 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42367 Mon 22 Aug 2022 14:08:53 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51365 Mon 22 Apr 2024 11:57:52 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46404 P = .002 vs controls), but not alcohol use. Infection with Helicobacter pylori was not associated with Menetrier’s disease (2.6% of patients vs 4.0% of controls; P = 1.00). There was no significant difference between patients with Menetrier’s disease vs controls in proportions with inflammatory bowel disease. Gastric cancer developed in 8.9% of patients with Menetrier’s disease by 10 years after the Menetrier’s disease diagnosis vs 3.7% of controls over the same time period (P = .09). Of patients with Menetrier’s disease, 72.7% and 65.0% survived for 5 and 10 years, respectively, compared with 100% of controls (P < .0001 for both time periods). Conclusions: In a case–control study of 76 patients with Menetrier’s disease, we found this rare disorder to be associated with increased mortality. Patients with Menetrier’s disease therefore should be followed up with surveillance endoscopy.]]> Mon 21 Nov 2022 15:15:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43435 P_app), with differences in ML retention and complexation amongst the chelants and the gut microbes. The decrease in ML permeability varied amongst the MLs. Chelating agents reduce intestinal absorption of MLs by forming complexes thereby making them less permeable. In the case of gut bacteria, the decrease in the intestinal permeability of MLs may be associated to a direct protection of the intestinal barrier against the MLs or indirect intestinal ML sequestration by the gut bacteria through adsorption on bacterial surface. Thus, both gut microbes and chelating agents can be used to decrease the intestinal permeability of MLs, thereby mitigating their toxicity.]]> Mon 19 Sep 2022 11:35:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51765 Cd > Pb > As(III)>As(V) for E. coli; and Hg > Cd > As(III)>Pb > As(V) for the two Lactobacillus sp. Arsenite (AsIII) showed higher toxicity than arsenate (AsV) to gut bacteria. While As is an anion, Cd, Pb and Hg are cations and hence their binding capacity to the bacterial cell wall varied based on the charge dependent functional groups. However, the toxic effects of PTEs for a bacteria are controlled by their speciation and bioavailability.]]> Mon 18 Sep 2023 14:23:29 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55689 Mon 17 Jun 2024 10:25:59 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50098 Mon 17 Jul 2023 11:05:36 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48303 Mon 15 May 2023 10:42:18 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53764 Mon 15 Jan 2024 09:56:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46229 Mon 14 Nov 2022 12:25:51 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46215 Mon 14 Nov 2022 12:04:53 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50967 Mon 14 Aug 2023 15:17:53 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53620 Mon 13 May 2024 12:39:54 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48208 Mon 08 May 2023 15:57:15 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51423 Mon 04 Sep 2023 14:58:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40025 Mon 04 Jul 2022 09:22:40 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55452 4 weeks are widely lacking. We evaluated the efficacy and safety of 8 weeks of treatment with the herbal combination product STW 5-II for patients with functional dyspepsia (FD) meeting Rome II criteria. We also conducted a post hoc analysis including patients meeting Rome IV criteria for FD and evaluated the effect of the G-protein beta 3 (GNB3) subunit polymorphism (C825T) on therapeutic response. Methods: This multicenter, placebo-controlled, double-blind study included 272 FD patients meeting Rome II criteria in the intention-to-treat cohort and 266 meeting Rome IV criteria. We used the validated Gastrointestinal Symptom Score (GIS) to assess GI symptoms, defining response rate as the proportion of patients with ≥50% GIS improvement in at least three of four assessments. Results: After 8 weeks, the response rate was significantly higher in the STW 5-II group versus placebo (61.2% vs 45.1%, P = 0.008). Mean GIS non-significantly improved with STW 5-II treatment (7.9 ± 4.41 vs 6.7 ± 4.91 with placebo; P = 0.07). In the Rome IV subgroup analysis, STW 5-II yielded a better response rate (P = 0.01) versus placebo and greater postprandial distress symptom improvement (P = 0.04) versus placebo. Safety parameters did not differ between groups, and GNB3 status was not linked with therapeutic response. Conclusion: STW 5-II is efficacious, with no observed safety signals at up to 8 weeks of treatment in patients with FD meeting Rome II or IV criteria.]]> Mon 03 Jun 2024 08:38:06 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45460 P = .37) but was significantly more prevalent in IBS-C as compared to IBS-D (OR = 3.1, 95% CI 1.7–5.6, P = .0001). The prevalence of methane-positive SIBO in patients with IBD was 3-fold lower at 7.4% (95% CI 5.4–9.8) compared to 23.5% (95% CI 19.8–27.5) in controls. The prevalence of methane positive SIBO was significantly lower in Crohn’s disease as compared to ulcerative colitis, (5.3%, 95% CI 3.0–8.5 vs. 20.2%, 95% CI 12.8–29.4). This systematic review and meta-analysis suggests methane positivity on breath testing is positively associated with IBS-C and inversely with IBD. However, the quality of evidence is low largely due to clinical heterogeneity of the studies. Thus, causality is uncertain and further studies are required.]]> Fri 28 Oct 2022 14:29:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52808 Fri 27 Oct 2023 14:20:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39241 P = 0.022 adjusted for age, sex, and smoking). Cecal IELs were increased in IBS—diarrhea (relative risk ratio = 2.03, 95% confidence interval 1.13–3.63, P = 0.017). No difference was observed in alpha diversity of MaM or fecal microbiota based on IEL count. There was no difference in beta diversity of the MaM according to IEL count in the terminal ileal (TI) (P = 0.079). High TI IEL counts associated with a significant expansion of the genus Blautia (P = 0.024) and unclassified Clostridiales (P = 0.036) in colon MaM. Discussion: A modest but significant increase in IELs was observed in IBS vs. controls in a population-based setting. Subtle TI and cecal inflammation may play a pathogenic role in IBS but needs confirmation. Modest but discernible differences in the colonic MaM were seen according to TI IEL count but not IBS status.]]> Fri 27 May 2022 14:39:27 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39212 Lactobacillus acidophilus, Lactobacillus rhamnosus and Escherichia coli. Lead toxicity to these three microbes was also examined at various pH values. Bioaccessibility of Pb was measured using gastric and intestinal extractions. Both Pb spiked and Pb-contaminated shooting range field soils were used to measure Pb bioaccessibility in the presence and absence of gut microbes. The results indicated that Pb toxicity to gut microbes, as measured by LD₅₀ value, decreased with increasing pH, and was higher for Lactobacillus species. Gut microbes decreased the bioaccessible Pb; the effect was more pronounced at low pH, mimicking gastric conditions than in conditions closer to the intestine. Lead adsorption by these microbes increased at the higher pH tested, and E. coli adsorbed higher amounts of Pb than did the Lactobacillus species. The effect of gut microbes on reducing Pb bioaccessibility may be attributed to microbially-induced immobilization of Pb through adsorption, precipitation, and complexation reactions. The study demonstrates that bioaccessibility and subsequently bioavailability of metal(loid)s can be modulated by gut microbes, and it is important to undertake bioaccessibility measurements in the presence of gut microbes.]]> Fri 27 May 2022 11:09:22 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49999 Fri 23 Jun 2023 11:40:47 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51947 Fri 22 Sep 2023 17:06:11 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51590 Fri 22 Sep 2023 13:41:03 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40059 Fri 22 Jul 2022 10:05:54 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53126 Fri 17 Nov 2023 12:21:21 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39693 Fri 17 Jun 2022 16:07:04 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51709 Fri 15 Sep 2023 14:09:51 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39981 Helicobacter pylori microbiota might account for some cases with unexplained chronic gastritis that may in a minority eventually progress to gastric cancer through the Correa cascade. We characterized gastric microbiota by describing the normal stomach, compared it with early precancerous lesions and other disease states, and assessed whether H. pylori status affects bacterial diversity. Methods: In a population-based study of those with and without gastrointestinal symptoms, cytology brush samples were collected during endoscopy from 316 individuals. Mucosal status was classified as normal mucosa (171), nonatrophic H. pylori gastritis (33), atrophic gastritis (12), or antral chemical gastritis (61). The 16S rRNA gene sequencing and analysis were performed to characterize the microbiota. Results: Microbiota in atrophic gastritis and nonatrophic H. pylori gastritis stomachs were dysbiotic and differed from those in the normal stomach (P = 0.001). The normal stomach had the highest microbial diversity, followed by antral chemical gastritis. The atrophic gastritis and chronic H. pylori gastritis groups had the lowest diversity, a difference that was statistically significant (P = 0.01). Besides H. pylori, non–H. pylori bacteria accounted for group differences. Microbial network analysis showed that the normal group network was most highly connected, whereas the H. pylori gastritis group had the lowest connection. We found an increasing positive co-occurrence of oral bacteria in the stomach because samples deviated from the normal network, some of which were pathogens. The H. pylori–negative group had the highest microbial diversity (Shannon index) compared with the H. pylori–positive group (P = 0.001). Discussion: In this low–H. pylori prevalence general population, the gastric mucosal microbiota of the normal stomach differed significantly from those with nonatrophic or atrophic gastritis. There was an increasing abundance of pathogenic bacteria from the normal state to early precancerous states.]]> Fri 15 Jul 2022 10:16:11 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49401 Fri 12 May 2023 14:41:29 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49370 Fri 12 May 2023 13:38:14 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46130 Fri 11 Nov 2022 15:21:48 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36857 Fri 10 Jul 2020 19:14:46 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49881 Fri 09 Jun 2023 10:36:37 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49104 Fri 05 May 2023 11:32:06 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45748 Fri 04 Nov 2022 10:26:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39978 Fri 01 Jul 2022 09:58:32 AEST ]]>